Natural Killer (NK) Cell Transplantation for AML

Completed 49 enrolled St. Jude Children's Research Hospital

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.

Timeline

Start: 2005-09
Primary completion: 2012-02
Completion: 2013-03

Publications

Results Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010 Feb 20;28(6):955-9. doi: 10.1200/JCO.2009.24.4590. Epub 2010 Jan 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Clofarabine	Other / unclassified	40 mg/m2	Intravenous
Background	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	400 mg/m2	Intravenous
Background	Etoposide	Small molecule	100 mg/m2	Intravenous
Background	Fludarabine	Small molecule	25 mg/m2	Intravenous
Background	aldesleukin	Protein / enzyme biologic	1e+06 iu	Subcutaneous

Natural Killer (NK) Cell Transplantation for AML

Summary

Timeline

Publications

Drugs

Indications